Research programme: tuberculosis therapeutics - Indian Institute of Science/Vichem Chemie

Drug Profile

Research programme: tuberculosis therapeutics - Indian Institute of Science/Vichem Chemie

Latest Information Update: 17 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Indian Institute of Science; Vichem Chemie
  • Developer Hungarian Academy of Sciences; Indian Institute of Science; Vichem Chemie
  • Class
  • Mechanism of Action DNA topoisomerase inhibitors; Phosphatidyl myo inositol mannosyltransferase PimA inhibitors; Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Tuberculosis

Most Recent Events

  • 04 Mar 2015 Early research in Tuberculosis in Hungary (unspecified route)
  • 04 Mar 2015 Early research in Tuberculosis in India (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top